EPRX
NASDAQ
$6.24
Eupraxia Pharmaceuticals Inc (EPRX)
Eupraxia Pharmaceuticals Inc. (EPRX) is a clinical-stage biotechnology company focused on advancing its proprietary drug delivery technology and the development of innovative therapies for pain and inflammatory diseases. The company's lead candidates target localized pain conditions through its Elastomeric Plasmid Delivery System, which enhances the delivery and efficacy of biologics. With a robust pipeline and a commitment to addressing significant unmet medical needs, Eupraxia aims to revolutionize the standard of care in pain management. The company is leveraging its technology platform to establish strategic partnerships and drive future growth in the dynamic biopharmaceutical landscape.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $16.28 (+160.90%)
Market Cap
$339M
Free Cash Flow Yield
-8.43%
Beta (5Y)
0.76
Price Chart
Valuation
Market Cap$339M
P/B3.82
Profitability
EBITDA-$38M
EPS-$0.74
Financial Health
Free Cash Flow Yield-8.43%
Growth & Risk
Beta (5Y)0.76
Sharpe Ratio0.47